Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3987984 | 0.88 | GABRA1 (0.42) | GABRA1GABRB2MEN1KMT2AALDH1A1 | |
| SCHEMBL28519211 | 0.84 | KDM4E (0.42) | LMNAMEN1KMT2AKDM4E | |
| SCHEMBL26602346 | 0.79 | NPC1 (0.44) | PDE3BPDE3ALMNAL3MBTL1MEN1 | |
| SCHEMBL22927013 | 0.78 | NPC1 (0.43) | PDE3BPDE3ALMNAL3MBTL1MEN1 | |
| SCHEMBL16336730 | 0.78 | NR4A2 (0.43) | GABRA1GABRB2GABRB1GABRA3LMNA | |
| SCHEMBL21458296 | 0.77 | NPC1 (0.42) | PDE3BPDE3ALMNAL3MBTL1MEN1 | |
| SCHEMBL21458224 | 0.71 | PDE3B (0.42) | PDE3BPDE3ALMNAL3MBTL1MEN1 | |
| SCHEMBL12584005 | 0.70 | MAPT (0.45) | PDE3BPDE3ALMNAKMT2AALDH1A1 | |
| SCHEMBL26602513 | 0.69 | HSP90AA1 (0.42) | LMNAL3MBTL1KMT2AALDH1A1KDM4E | |
| SCHEMBL16341783 | 0.69 | CNR2 (0.63) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353829-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12215093-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-3781550-B1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS INC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240150316-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| CN-112313208-B | Bicyclic carboxamides and methods of use thereof | 泰普斯特医疗公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11472789-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| WO-2019204523-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | GABRA1 180/4885GABRB2 177/4885GABRB1 308/4885 |
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | GABRA1 180/4885GABRB2 177/4885GABRB1 308/4885 |
| US-20240150316-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | GABRA1 180/4885GABRB2 177/4885GABRB1 308/4885 |
| US-11472789-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | GABRA1 180/4885GABRB2 177/4885GABRB1 308/4885 |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | GABRA1 180/4885GABRB2 177/4885GABRB1 308/4885 |
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | GABRA1 180/4885GABRB2 177/4885GABRB1 308/4885 |
| US-20250353829-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | GABRA1 180/4885GABRB2 177/4885GABRB1 308/4885 |
| US-12215093-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | GABRA1 180/4885GABRB2 177/4885GABRB1 308/4885 |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | GABRA1 180/4885GABRB2 177/4885GABRB1 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.